 Eligible patients will receive a minimum of six cycles of combination therapy. If a patient is still responding to the oxaliplatin at 6 cycles, the oxaliplatin may be continued with the trastuzumab up to 10 cycles at the investigators discretion. After discontinuing the oxaliplatintrastuzumab combination, patients should continue with single agent trastuzumab until disease progression. 